当前位置: 首页   >   科研与学术   >   正文

重点实验室副主任孙英贤教授研发高血压防控“中国方案”获全球推荐

作者:    信息来源:    发布时间: 2025-10-10

重点实验室副主任孙英贤教授带队研发的“中国农村高血压控制模式”被《2025全球高血压报告》作为中国唯一入选模式向全球推荐。

我国高血压患者人数约2.7亿,有效控制率仅18%,而高血压是导致我国居民罹患心脑血管疾病最重要的危险因素。肥胖不仅会增加高血压的发病风险,还会提高高血压并发症,如心脑血管疾病的发生率。孙英贤教授长期致力于高血压等慢性病的防控研究,牵头主持科技部重点研发项目等多项国家级重大重点项目,研究覆盖多地超百万人口,大幅提升高血压控制率、降低心脑血管事件及死亡风险,相关成果多次登上国际顶级期刊《柳叶刀》。孙英贤教授团队在“强化降压”领域的研究为高血压治疗提供依据,其构建的评估框架显示强化降压更具优势。

孙英贤教授团队将继续推广农村高血压控制模式,同时深化降压精准化研究,助力我国从高血压“高患病、低控制”向“科学防控、有效管理”转变,为全球高血压防控贡献中国智慧。


代表性成果:

1. Xiaofan Guo, Guozhe Sun, Yu Xu, Shiyu Zhou, Qirui Song, Yan Li, Nanxiang Ouyang, Guangxiao Li, Zhongde Cheng, Ning Ye, Jun Wang, Ying Zhou, Hongmei Yang, Chuning Shi, Chang Wang, Songyue Liu, Wensheng Zhu, Andrew E Moran, Guang Ning, Yufang Bi, Weiqing Wang, Jun Cai, Jing Li, Yingxian Sun; BPRULE Study Group. Benefit-harm trade-offs of intensive blood pressure control versus standard blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of randomised controlled trials. Lancet. 2025 Sep 6;406(10507):1009-1019. doi: 10.1016/S0140-6736(25)01391-1. Epub 2025 Aug 31.

2. Jiang He, Nanxiang Ouyang, Xiaofan Guo, Guozhe Sun, Zhao Li, Jianjun Mu, Dao Wen Wang, Lixia Qiao, Liying Xing, Guocheng Ren, Chunxia Zhao, Ruihai Yang, Zuyi Yuan, Chang Wang, Chuning Shi, Songyue Liu, Wei Miao, Guangxiao Li, Chung-Shiuan Chen, Yingxian Sun; CRHCP Study Group. Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial. Lancet. 2023 Mar 18;401(10380):928-938. doi: 10.1016/S0140-6736(22)02603-4. Epub 2023 Mar 2.

3. Yingxian Sun, Jianjun Mu, Dao Wen Wang, Nanxiang Ouyang, Liying Xing, Xiaofan Guo, Chunxia Zhao, Guocheng Ren, Ning Ye, Ying Zhou, Jun Wang, Zhao Li, Guozhe Sun, Ruihai Yang, Chung-Shiuan Chen, Jiang He; CRHCP Study Group. A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial. Lancet. 2022 May 21;399(10339):1964-1975. doi: 10.1016/S0140-6736(22)00325-7. Epub 2022 Apr 29.

4. Global report on hypertension 2025: high stakes: turning evidence into action. https://www.who.int/publications/i/item/9789240115569


中国医科大学 环境应激与慢病防控教育部重点实验室 版权所有